Literature DB >> 19720893

Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.

Heikki J Järvinen1, Laura Renkonen-Sinisalo, Katja Aktán-Collán, Päivi Peltomäki, Lauri A Aaltonen, Jukka-Pekka Mecklin.   

Abstract

PURPOSE: Colonoscopies with polypectomies and endometrial biopsies with transvaginal ultrasonography, repeated at 2- to 3-year intervals, are performed for prevention or early detection of cancer in patients with DNA mismatch repair gene mutation causing Lynch syndrome. The long-term effectiveness of surveillance was evaluated in Lynch syndrome family members tested approximately 10 years ago.
MATERIALS AND METHODS: Cancer incidence and survival were determined after an 11.5-year follow-up in 242 mutation-positive and 367 mutation-negative participants. These participants in 57 Lynch syndrome families with 14 different mutations were at 50% risk. The median age was 36 years (range, 18 to 72 years) in mutation carriers and 42 years (range, 18 to 72 years) in mutation-negative participants, and none had had cancer of the Lynch syndrome type.
RESULTS: Compliance was 95.9% for the colonic surveillance and 97.1% for the gynecologic surveillance. Colorectal cancer (CRC) occurred in 30 mutation-positive participants, and 74 participants had adenomas removed. Three patients died of CRC. Endometrial cancer (EC) occurred in 19 of 103 women at risk, and 48 women had prophylactic hysterectomy. Six of 112 women at risk had ovarian cancer. The overall cancer risk ratio (RR) in mutation carriers was 5.80 (95% CI, 3.4 to 9.5). Cancer mortality rate (RR = 2.28; 95% CI, 0.82 to 6.31) and overall death rate (RR = 1.26; 95% CI, 0.65 to 2.46) were not significantly increased.
CONCLUSION: Long-term compliance in surveillance for CRC and EC exceeded 95% in Lynch syndrome. All CRC deaths were not prevented as a result of noncompliance or missed lesions. Still, after 10 years of surveillance, no significant increase in mortality had occurred compared with mutation-negative relatives.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19720893     DOI: 10.1200/JCO.2009.23.7784

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  91 in total

1.  Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome.

Authors:  L H Katz; A M Burton-Chase; S Advani; B Fellman; K M Polivka; Y Yuan; P M Lynch; S K Peterson
Journal:  Clin Genet       Date:  2015-09-14       Impact factor: 4.438

2.  Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation.

Authors:  Patrizia Lastella; Margherita Patruno; Giovanna Forte; Alba Montanaro; Carmela Di Gregorio; Carlo Sabbà; Patrizia Suppressa; Adalgisa Piepoli; Anna Panza; Angelo Andriulli; Nicoletta Resta; Alessandro Stella
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 3.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

4.  Preferences for genetic testing for colorectal cancer within a population-based screening program: a discrete choice experiment.

Authors:  Jorien Veldwijk; Mattijs S Lambooij; Frank G J Kallenberg; Henk J van Kranen; Annelien L Bredenoord; Evelien Dekker; Henriëtte A Smit; G Ardine de Wit
Journal:  Eur J Hum Genet       Date:  2015-06-03       Impact factor: 4.246

Review 5.  Lynch syndrome: clinical, pathological, and genetic insights.

Authors:  Ralph Schneider; Claudia Schneider; Matthias Kloor; Alois Fürst; Gabriela Möslein
Journal:  Langenbecks Arch Surg       Date:  2012-02-24       Impact factor: 3.445

6.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  High risk for neoplastic transformation of endometriosis in a carrier of Lynch syndrome.

Authors:  Christine Nyiraneza; Etienne Marbaix; Mireille Smets; Christine Galant; Christine Sempoux; Karin Dahan
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

8.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

9.  Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer: A Population-based Study.

Authors:  Elena M Stoffel; Rune Erichsen; Trine Frøslev; Lars Pedersen; Mogens Vyberg; Erika Koeppe; Seth D Crockett; Stanley R Hamilton; Henrik T Sørensen; John A Baron
Journal:  Gastroenterology       Date:  2016-07-19       Impact factor: 22.682

10.  Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Authors:  Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.